Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% - Should You Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) dropped 4.7% on Friday . The company traded as low as $9.63 and last traded at $9.74. Approximately 48,133 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 80,171 shares. The stock had previously closed at $10.22.

Wall Street Analyst Weigh In

Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating on the stock.

Gyre Therapeutics Trading Down 1.7 %

The company has a 50 day simple moving average of $11.29 and a 200 day simple moving average of $12.18. The stock has a market cap of $847.66 million, a P/E ratio of 181.08 and a beta of 1.93.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The firm had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 36,054 shares of company stock worth $407,317. Company insiders own 19.52% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. Geode Capital Management LLC grew its position in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after buying an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock valued at $1,386,000 after purchasing an additional 918 shares during the last quarter. State Street Corp boosted its position in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock valued at $1,310,000 after buying an additional 8,412 shares in the last quarter. Northern Trust Corp boosted its position in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after buying an additional 8,624 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Gyre Therapeutics during the fourth quarter worth $1,225,000. 23.99% of the stock is owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.